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lipidaemias and overweight/obesity significantly impact on kidney transplant (KT) outcomes.
This joint position statement is based on the evidence on the management of metabolic alter-
ations in KT recipients (KTRs) published after the release of the 2009 KDIGO clinical practice
guideline for the care of KTRs. Members of the Italian Society of Nephrology (SIN), the Italian So-
ciety for Organ Transplantation (SITO) and the Italian Diabetes Society (SID) selected to represent
professionals involved in the management of KTRs undertook a systematic review of the pub-
lished evidence for the management of PTDM, dyslipidaemias and obesity in this setting. The
aim of this work is to provide an updated review of the evidence on the prevention, diagnosis
and treatment of metabolic alterations in KTRs, in order to support physicians, patients and
the Healthcare System in the decision-making process when choosing among the various avail-
able options.
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2 C. Conte et al.Introduction
Kidney transplant (KT) is the only definitive cure for end-
stage renal disease (ESRD). With more than 21,200 and
2100 KTs performed in 2018 in Europe and Italy, respec-
tively [1], KT is by far the most commonly performed
transplant procedure. Graft and recipient survival have
dramatically improved over the last decades, and the age
range for entering the wait list has broadened to include
older recipients [2]. In this context, the impact of chronic
metabolic alterations on KT outcomes has become
increasingly relevant [3]. Post-transplant diabetes mellitus
(PTDM), which includes both undiagnosed pre-existing
diabetes and new onset diabetes after KT [4], is reported
in 10e20% of KT recipients (KTRs) and may severely affect
both short- and long-term outcomes in this population [5].
Furthermore, many KTRs have long-standing diabetes that
is often the underlying cause of ESRD leading to KT. In
KTRs aged 60 years presence of diabetes in the later post-
transplant period is an independent predictor of increased
mortality [6]. Dyslipidaemias and overweight/obesity are
also very common metabolic disturbances among KTRs
that may undermine graft and/or recipient outcomes
[7e9].
Current guidelines on the management of metabolic
alterations in KTRs include the 2009 Kidney Disease:
Improving Global Outcomes (KDIGO) clinical practice
guideline on the monitoring, management, and treatment
of kidney transplant recipients [10] and the recommen-
dations based on the proceedings from an international
consensus meeting on PTDM [4]. More recently, recom-
mendations on the management of dyslipidaemia in pa-
tients with chronic kidney disease (CKD) including KTRs
have been endorsed by the Italian Society of Nephrology
(SIN) [9].
The College of the Italian Societies of Nephrology and
Organ Transplantation (Collegio SIN-SITO) for kidney and
pancreas transplantation, which has the scope of i) ana-
lysing the specific organisational and clinical aspects of
kidney and pancreas donation and transplantation ac-
tivities ii) developing and coordinating research, the ex-
change of scientific information, professional training,
multicentre studies; iii) promoting actions to optimise
the clinical care pathways targeted to patients who can
benefit from transplantation and transplant patients; and
iv) defining guidelines, identified the need to provide
updated guidance on the management of metabolic al-
terations in adult KTRs and promoted the work that led to
the development of this document. This joint position
statement is based on the evidence on the management
of metabolic alterations in KTRs published after the
release of the 2009 KDIGO clinical practice guideline for
the care of KTRs [10]. Members of the SIN, the Italian
Society for Organ Transplantation (SITO) and the Italian
Diabetes Society (SID) selected to represent professionals
involved in the management of KTRs undertook aPlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orsystematic review of the evidence on the management of
PTDM, dyslipidaemias and obesity in adult KTRs pub-
lished in the last 10 years. Only articles published in En-
glish were eligible. When no new evidence was found,
recommendations were based on expert opinion and
previous guidelines [4,10e22]. The aim of this work is to
provide an updated review of the evidence on the pre-
vention, diagnosis and treatment of metabolic alterations
in KTRs, in order to support physicians, patients and the
Healthcare System in the decision-making process when
choosing among the various available options. The posi-
tion statement addresses the management of adult KTRs
and is targeted to healthcare professionals involved in KT,
particularly nephrologists, diabetologists and transplant
surgeons. The position statement does not intend to
define a standard of treatment, nor to establish in-
dications or absolute contraindications. Indeed, the
choice of treatment is individual, and depends on several
factors such as the expected risk/benefit ratio for the in-
dividual patient, her/his preferences, and the availability
of healthcare resources.
The strength of recommendations and the quality of
evidence were reported according to the GRADE (Grading
of Recommendations Assessment, Development and
Evaluation) system [23]. Recommendations are classified
into one of two grades (grade 1: strong recommendation;
grade 2: weak recommendation), while the quality of the
evidence is classified into one of four categories (ØOOO,
very low; ØØOO, low; ØØØO, moderate; ØØØØ, high).
Recommendations with no grade were classified as “not
graded”.Screening for post transplant diabetes mellitus (PTDM)
A diagnosis of PTDM should be made according to the
American Diabetes Association criteria, which include
glucose (fasting or 2-h during a 75-g oral glucose tolerance
test [OGTT]) and HbA1c criteria [4,11]. The available evi-
dence on the optimal screening timing for each criterion is
of low quality and is discussed below.
Hyperglycaemia is very common in the early post-
operative period after KT [24], with peaks in the afternoon
that likely reflect glucocorticoid kinetics [25,26]. In the
first 6 weeks after KT, afternoon capillary blood glucose
testing might be more sensitive than other tests in
detecting patients at risk for PTDM [26]. In addition,
bedside capillary glucose 200 and fasting plasma glucose
(FPG) measured early after KT identify patients at risk for
PTDM [27,28], prompting the need for closer monitoring
during follow-up. However, many patients with hyper-
glycaemia in the early postoperative period show signifi-
cant improvements both in glycaemic control and
variability in the following months [25]. Thus, as previ-
ously recognized by a consensus of international experts, a
formal diagnosis of PTDM is best made when patients are
stable on their likely maintenance immunosuppression,lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
g/10.1016/j.numecd.2020.05.004
1 We recommend screening all non-diabetic
KTRs, at least:
 perioperatively with fasting plasma
glucose and bedside capillary glucose
(2ØØOO);
 every 3 months for 1 year with fasting
plasma glucose and HbA1c and/or oral
glucose tolerance test (OGTT) (2ØØOO);
and
 annually thereafter, with fasting plasma
glucose and HbA1c, unless otherwise clin-
ically indicated. (2ØØOO)
2 We suggest screening for PTDM with fasting
glucose, HbA1c and/or OGTT after starting,
or substantially increasing the dose, of CNIs,
mTORi, or corticosteroids, and when known
risk factors for PTDM are identified during
follow-up. (2ØOOO)
CNI, calcineurin inhibitor; HbA1c, haemoglobin
A1c; KTRs, kidney transplant recipients;
mTORi, mammalian target of rapamycin in-
hibitor(s); PTDM, new-onset diabetes after
transplantation.
Metabolic alterations in kidney transplant 3with stable kidney graft function and in the absence of
acute infections [4].
Diagnosis of PTDM is preferably based on OGTT results
[4]. Nevertheless, OGTT is time-consuming, and not
routinely performed. For this reason, alternative screening
methods have been evaluated.
In the initial months after KT (10 weekse4 months), the
specificity of HbA1c  6.5% (48 mmol/mol) for diagnosing
PTDM is as high as 96%, but the sensitivity is low (48%)
[29]. Lowering the HbA1c threshold to 6.2% (44 mmol/
mol) increased the sensitivity by nearly 30% and decreased
specificity by 10%. The relatively low sensitivity of HbA1c
in the early post-transplant period limits its use as indi-
vidual screening test. Furthermore, HbA1c should not be
used as the only screening test in the first months after
transplant, when factors such as post-operative anaemia,
erythropoietin use, and blood transfusions may mine its
reliability. As such, we suggest using HbA1c in conjunction
with FPG to screen for PTDM in the first months following
KT. It has also been suggested that a FPG between 5.3 and
6.9 mmol/L, HbA1c  5.8% (40 mmol/mol), or a
FPG  5.0 mmol/L combined with HbA1c  5.7%
(39 mmol/mol) in the early post-transplant period (10
weeks) should prompt an OGTT in order to increase the
likelihood of detecting undiagnosed PTDM [30].
As OGTT for diagnosing PTDM at 10 weeks post-
transplantation has demonstrated superiority versus
HbA1c with regard to prediction of long-term outcomes
(i.e. mortality) in patients without overt diabetes [31], we
suggest considering performing an OGTT 2e3 months
following KT to screen for PTDM, particularly in those
KTRs with combined FPG 5.0 mmol/L (90 mg/dL) and
HbA1c  5.7% (39 mmol/mol) [30].
In a retrospective analysis of nearly 500 KTRs without
known diabetes who underwent comprehensive assess-
ment of glycaemic status at one year after transplant,
including HbA1c, FPG and OGTT, using HbA1c alone
(6.5% or 48 mmol/mol) resulted in a specificity of 97%
and sensitivity of 43% [32]. This finding is in line with
those of a systematic review and metanalysis showing
that HbA1c  6.5% (48 mmol/mol) had a sensitivity of
40% and specificity of 94% for diagnosing PTDM one year
after KT [29]. Combining FPG and HbA1c criteria for
diagnosing PTDM captured almost all patients with
persistent PTDM (area under the receiver operating
characteristics [AUROC] versus OGTT 0.86). After the first
year post-transplantation, during which PTDM incidence
is the greatest [33e37], continuous screening is recom-
mended, at least annually. In fact, glucose metabolism
after transplantation is highly dynamic, with glucose
metabolism either deteriorating or improving over time
in individual patients even after the first year [38],
highlighting the need for continuous screening. Although
studies with larger sample size and longer follow-up are
needed to better evaluate the diagnostic accuracy of FPG
and HbA1c after the first year following KT, it seems
reasonable to screen patients with FPG and HbA1c
annually, unless otherwise indicated based on clinical
conditions.Please cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orFinally, we suggest screening for PTDM after initiating
or substantially increasing the dose of potentially diabe-
togenic drugs commonly used in the management of KTRs
(e.g. steroids, calcineurin inhibitors and HMG CoA reduc-
tase inhibitors) [5,39], as well as when known risk factors
for PTDM (e.g. central obesity or significant weight gain,
increasing age, hypomagnesaemia, HCV and cytomegalo-
virus infections) [5,39] are detected.Managing PTDM or diabetes Present at transplantation
Immunosuppressive regimen
At the time the KDIGO guidelines were published, there
were no RCTs testing whether changing to different
immunosuppressive regimens could reverse or ameliorate
PTDM [10]. The KDIGO guidelines acknowledged that,
given the associations of PTDM with CsA, tacrolimus,
mTORi and corticosteroids, it was plausible that reducing
or eliminating these immunosuppressive medications
could reverse or ameliorate PTDM. Since then, few studies
have been conducted to establish the benefits and harms
of altering the immunosuppressive medication regimen in
response to the development of PTDM.lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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1 If PTDM develops, consider modifying the
immunosuppressive drug regimen to
reverse or ameliorate diabetes, after weigh-
ing the risk of rejection and other potential
adverse effects. (2ØØØO)
4 C. Conte et al.Changes in immunosuppressive medications that have
been assessed in either randomized or retrospective
controlled studies include:
i) Conversion from tacrolimus to cyclosporine.
Significantly greater incidence rates of PTDM were
reported with high-level tacrolimus (trough 8e12 lg/
L) and low-level sirolimus (3e7 mg/L) both versus
cyclosporine plus MMF and low-level tacrolimus
(trough 3e7 mg/L) and high-level sirolimus (8e12 mg/
L) in KTRs subjected to rapid discontinuation of
prednisone, suggesting that high-dose tacrolimus
might be associated with diabetogenic effects [40].
In a small case series, conversion of KTRs with PTDM
from tacrolimus to cyclosporine improved fasting
plasma glucose in the short term (6 months), but the
benefit was lost thereafter [41]. More recently, a
randomized prospective study showed that conver-
sion from tacrolimus to cyclosporine was associated
with the reversal of PTDM in a significantly higher
proportion of patients (34% versus 10%) at 12 months
[42]. Conversion to cyclosporine was also associated
with better glycaemic control (HbA1c), and signifi-
cantly more patients free of glucose-lowering ther-
apy, with no increase in the incidence of acute graft
rejection. Nevertheless, patients switched to cyclo-
sporine exhibited a reduction in renal function, a
mild elevation in LDL cholesterol, and a numerically
higher incidence of infectious episodes. Finally,
switch to CsA was mostly effective in milder forms of
PTDM, whereas it was less so in patients with PTDM
requiring antihyperglycaemic drugs.
ii) Conversion from CNI to mTORi. A post-hoc analysis
of two large randomized trials (ZEUS and HERAKLES)
found no difference in the incidence or severity of
PTDM in patients who were converted early post-
transplant from a CsA-based regimen to ever-
olimus, nor in the progression of pre-existing dia-
betes [43]. There is some evidence that switching
from a CNI-based immunosuppressive regimen to an
mTORi-based immunosuppressive regimen might
lead to remission of PTDM [44].
We could not find any published reports on the effects
of reducing the dose of tacrolimus, CsA or corticosteroids;
replacing tacrolimus or CsA with MMF or azathioprine;
reducing the dose or discontinuing a mTORi on PTDM. One
small retrospective, non-controlled trial showed that
switching patients with PTDM from methylprednisolone
to everolimus on top of tacrolimus and MMF did not
worsen HbA1c over time [45]. An extension of this trial
showed a significant decrease in HbA1c levels 9 months
after conversion from methylprednisolone to everolimus
[46]. Furthermore, at 12 months HbA1c was <6.5%, and
renal function remained stable.
As for corticosteroids, steroid avoidance or early
withdrawal has been advocated as a potential strategy to
reduce the incidence of PTDM. Rapid discontinuation of
prednisone (5 days after KT) was associated withPlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orsignificantly lower incidence rates of PTDM in KTR versus
historical controls on prednisone maintenance therapy
[47]. The authors of a Cochrane review that assessed the
benefits and harms of steroid withdrawal or avoidance for
KTRs concluded that it was not possible to clearly
demonstrate a reduction in PTDM within five years after
transplantation for steroid withdrawal or avoidance in
adult KTRs [48]. There was, however, a significant 77% and
58% increase in acute rejection after steroid withdrawal or
avoidance, respectively. More recently, a discrete event
simulation based on data from over 55,000 KTRs in the
United States suggested that strategies of 6-and 12-month
steroid withdrawal after kidney transplantation might
reduce the rates of PTDM and cardiovascular (CV) events
with no worsening of acute rejection or graft loss rates
compared with steroid maintenance [49]. Furthermore, in
a 6-week randomized study that compared two
prolonged-release tacrolimus corticosteroid minimization
regimens, incidence of PTDM was similarly low in the two
treatment arms (17.4% vs. 16.6%; PZ 0.579), but the 10-day
steroid tapering regimen in conjunction with prolonged
release tacrolimus plus MMF had a lower incidence of
biopsy-proven acute rejection versus a single bolus of
steroid in conjunction with prolonged-release tacrolimus
plus MMF [50].Glycaemic targets
Tight blood sugar control reduces the risk of developing
microvascular diabetes complications both in type 1 and
type 2 diabetes [51e54], and the benefits associated with
good glycaemic control persist over time [55e57]. Simi-
larly, a reduction in CV events has been reported both in
patients with type 1 and type 2 diabetes subjected to early
intensive glycaemic control decades after the intervention
[57e60].
Recent European and American guidelines on the
management of diabetes state that a reasonable HbA1c
goal for many adults with diabetes is <7% (53 mmol/mol)
[12,16]. More stringent goals (e.g. <6.5% or 48 mmol/mol)
might be suggested for selected patients if this can be
achieved without significant hypoglycaemia or other
adverse effects of treatment (i.e., polypharmacy). On thelterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
g/10.1016/j.numecd.2020.05.004
Metabolic alterations in kidney transplant 5other hand, less stringent goals (up to <8e9%
[64e75 mmol/mol]) may be appropriate for patients with
a history of severe hypoglycaemia, limited life expectancy,
advanced microvascular or macrovascular complications,
multiple comorbidities, or long-standing diabetes in
whom the goal is difficult to achieve [12,16]. To the best of
our knowledge, only one study addressed the issue of
glycaemic targets in diabetic KTRs since the publication of
the KDIGO guidelines [61]. In this large retrospective
cohort study of KTRs who underwent transplantation due
to diabetic nephropathy, those with HbA1c between 7.6%
and 8.6% (60 and 70 mmol/mol, mean 8.1  0.3%
[65  2.4 mmol/mol]) had the best graft outcomes. Based
on the above, and considering that KTRs are at increased
CV risk as compared with the general population, it seems
reasonable to suggest an HbA1c target of 7e8%
(53e64 mmol/mol) [62].
HbA1c may be unreliable indicator in the early post-
transplant period [3,4]. Self-glucose monitoring should be
encouraged for KTRs with PTDM in the first months after
transplantation and continued thereafter in those on in-
sulin or insulin secretagogues, aiming at pre-prandial
capillary plasma glucose of 80e130 mg/dL
(4.4e7.2 mmol/L) and peak postprandial capillary plasma
glucose < 180 mg/dL (10.0 mmol/L) as for the general
population with diabetes [12].1 We suggest targeting HbA1c 7.0e8.0% (53
e64 mmol/mol) and avoiding a target HbA1c
<6.0% (42 mmol/mol), especially if hypo-
glycaemic reactions are common. (Not
Graded )
2 We suggest encouraging self glucose moni-
toring for KTRs with PTDM in the first
months after transplantation and continuing
it thereafter in those on insulin or insulin
secretagogues, aiming at pre-prandial capil-
lary plasma glucose of 80e130 mg/dL (4.4
e7.2 mmol/L) and peak postprandial capil-
lary plasma glucose <180 mg/dL (10.0 mmol/
L) as for the general population with diabetes
(Not Graded )
1 In the inpatient setting we recommend initi-
ating insulin therapy for persistent hyper-
glycaemia starting at threshold >180
(10.0 mmol/L) and maintain a target glucose
range of 140e180 mg/dL (7.8e10.0 mmol/L)
(1ØØØO)Insulin therapy
Hyperglycaemia early after kidney transplantation is very
common [3,4], and is associated with subsequent devel-
opment of PTDM [27,63e65] and graft failure [64e66].
More in general, hyperglycaemia in hospitalised patients,Please cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orwith or without diabetes, is associated with adverse out-
comes including increased rates of infection and mortality,
and longer hospital length of stay [67]. Appropriate gly-
caemic control in the hospital setting can reduce the risks
and improve outcomes [14].
In non-diabetic KTRs participating in a randomized
controlled trial assessing the effectiveness and safety of
continuous subcutaneous insulin lispro infusion (CSII, pre-
supper BG target 110 mg/dL) as compared to basal insulin
treatment (pre-supper BG target 110 mg/dL) and standard
therapy (i.e. short-acting insulin lispro aiming at pre-lunch
and pre-supper blood glucose values < 200 mg/dL), CSII
resulted in significantly lower blood glucose levels during
the first week after kidney transplantation, as compared to
a basal insulin isophane regimen and to standard therapy
for most time points [68]. However, longer term results of
this study have not been published yet. Another random-
ized controlled trial that assessed intensive peri- and post-
transplant insulin therapy (aiming at a target blood
glucose < 121 mg/dL [6.7 mmol/L] on discharge) in KTRs
with type 1 or 2 diabetes did not reduce incidence of
delayed graft function but increased the incidence of
hypoglycaemia (but not severe hypoglycaemia) [69].
Furthermore, this regimen was associated with an
increased number of rejection episodes compared with
standard insulin therapy (subcutaneous insulin with a
basal plus bolus regiment aiming at a blood
glucose < 180 mg/dL [10 mmol/L] on discharge) [69].
Finally, in a third study non-diabetic KTRs were randomly
assigned to immediate-postoperative isophane insulin for
evening blood glucose 140 mg/dL (treatment group) or
short-acting insulin and/or oral antidiabetic agents for
blood glucose 180e250 mg/dL (standard therapy) [70].
KTRs in the treatment group had lower blood glucose
values during the hospital stay, and 73% lower odds of
PTDM than the control group throughout the 12-month
follow up. At one year, all patients in the treatment
group were insulin-independent, whereas nearly one third
of controls required antidiabetic agents.
It seems reasonable to suggest initiating early insulin
treatment insulin therapy for persistent hyperglycaemia
starting at threshold >180 (10.0 mmol/L) and maintain a
target glucose range of 140e180 mg/dL (7.8e10.0 mmol/L)
as in the general inpatient population [14].lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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1 In the outpatient setting we suggest consid-
ering the use of glucose-lowering agents
according to patient characteristics, renal
function and potential drugedrug in-
teractions (Not Graded ).
2 We suggest preferring glucose-lowering
agents with neutral or beneficial effects on
CV and renal outcomes that have been tested
in the KTR population (Not Graded )
6 C. Conte et al.Non-insulin hypoglycaemic agents
The 2009 KDIGO guidelines did not provide any specific
recommendation to guide treatment choices for PTDM
[10]. However, over the past decade there has been a
paradigm shift in the management of diabetes, due to the
advent of novel drugs (i.e. glucagon-like peptide 1 receptor
agonists [GLP-1RA] and sodium-glucose cotransporter-2
inhibitors [SGLT-2i]) that have been shown able to modify
CV risk and other important outcomes, including the
progression of chronic kidney disease (CKD) in patients
with type 2 diabetes [71]. Furthermore, more evidence is
now available to help clinicians when treating KTRs with
PTDM.
International guidelines recommend metformin as he
first-line therapy for most individuals with diabetes, un-
less contraindicated or not tolerated [71]. As metformin is
cleared by the kidneys and may increase the risk of lactic
acidosis, its use in patients with impaired kidney function
has been discouraged in the past. However, the European
Medicines Agency recently lowered the glomerular filtra-
tion rate (GFR) threshold below which metformin should
not be used, and the drug may now be prescribed to stable
patients with moderately reduced kidney function (GFR
30e59 mL/min) [72]. The maximum recommended dosage
in patients in patients with eGFR <45 mL/min is usually
1000 mg/day [73]. Moreover, transplant recipients on
metformin should be instructed to temporarily withdraw
the drug in conditions of pending dehydration or when
they undergo contrast media investigations or any other
situation that predisposes to an increased risk of acute
graft dysfunction [73,74]. A large retrospective cohort
study conducted in the U.S.A. investigated the frequency of
metformin use and its association with patient and graft
survival among KTRs [75]. The authors found that nearly
40% of KTRs with a metformin prescription had creatinine
levels above the threshold recommended by the Food and
Drug Administration. Nevertheless, no patient or allograft
survival disadvantage associated with metformin use. A
pilot randomised controlled trial of metformin in predia-
betes after KT is currently ongoing [76].
A Cochrane review published in 2017 specifically eval-
uated the efficacy and safety of pharmacological glucose
lowering interventions KTRs with diabetes [77]. It
encompassed 7 randomised controlled trials, including
nearly 400 KTRs. Antihyperglycaemic medications exam-
ined included insulin (intensive versus less intensive regi-
mens), DPP4 inhibitors (vildagliptin, sitagliptin), and
pioglitazone, with variable results. In particular, intensive
insulin regimens were associated with neutral or even
negative effect on rejection rates, and more hypoglycaemic
episodes. Studies on DPP-4 inhibitors showed neutral ef-
fects on kidney graft survival and renal function, better
glycaemic control versus placebo and comparable effect
versus insulin glargine. Furthermore, the safety profile and
incidence of hypoglycaemia were low and similar to pla-
cebo. Pioglitazone in conjunction with insulin therapy was
more effective than insulin alone in lowering HbA1c, and
was not associated with increased hypoglycaemia. ThePlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orauthors of the systematic review, however, concluded that
available data were limited and of low or very low quality.
More recently, the role of newer drugs in the manage-
ment of PTDM has also been assessed. A small retrospec-
tive case series of KTRs treated with the GLP-1RA
liraglutide suggested that this drug might be safe and
effective for treating PTDM [78]. Two studies have
assessed the role of SGLT-2i in the management of PTDM.
The first study was a small, single-arm pilot trial that
enrolled 25 KTRs with PTDM (20 had pre-existing dia-
betes) who were prescribed canagliflozin on top of stan-
dard antihyperglycaemic treatment [79]. Canagliflozin was
well tolerated, and significantly reduced blood pressure
and HbA1c, without affecting renal function nor tacroli-
mus levels. A recent randomized controlled trial of
empagliflozin in KTRs with PTDM demonstrated signifi-
cantly greater reductions in HbA1c, body weight, BMI, and
uric acid with empagliflozin versus placebo [80]. The
magnitude of HbA1c reduction was greater in those with
baseline HbA1c >8% (64 mmol/mol). Empagliflozin was
well tolerated, with no apparent interactions with
immunosuppressants.
Although further evidence is needed to support routine
use of SGLT-2i in KTRs with PTDM, these drugs are asso-
ciated with both CV and renal protective effects [81,82],
and may therefore be preferred over other agents that are
not associated with such beneficial effects and have not
been tested in the KTR population. On the other hand,
because of their mechanism of action, these drugs may be
less effective in reducing HbA1c in patients with impaired
renal graft function [83]. Finally, in choosing the most
appropriate glucose-lowering agent, drugedrug in-
teractions should always be taken into account [84].Aspirin
We could find no studies assessing the benefit and/or
harm of low-dose aspirin for the primary prevention of
CVD in KTRs with PTDM published after the KDIGO
guidelines were issued.lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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Guidelines on diabetes, pre-diabetes, and cardiovascular
diseases developed in collaboration with the European
Association for the Study of Diabetes (EASD) state that, in
patients with diabetes at high/very high risk, aspirin
(75e100 mg/day) may be considered in primary preven-
tion in the absence of clear contraindications [16]. This
statement is based on the findings of the ASCEND study,
which demonstrated a lower percentage of serious
vascular events in patients with diabetes and no evidence
of CV disease treated with aspirin versus placebo (8.5% vs.
9.6%; rate ratio, 0.88; P Z 0.01) [85]. Similarly, the 2019
ADA Standards of Care for Diabetes acknowledge that the
aspirin-associated absolute decrease in events depends on
the underlying CV risk, and state that low-dose aspirin
may be considered primary prevention strategy in those
with diabetes who are at increased CV risk, after discus-
sing with the patient on the benefits versus increased risk
of bleeding [13]. When compared to the general popula-
tion, in KTRs requiring urgent graft biopsy aspirin may
have the additionally disadvantage of increasing the risk of
bleeding and/or of delaying the time of biopsy.
Aspirin for primary prevention is not recommended in
patients with diabetes at moderate CV risk. When low-
dose aspirin is used, proton pump inhibitors should be
considered to reduce the risk of gastrointestinal bleeding
[86,87].
Individuals with diabetes and CV disease, or diabetes
with target organ damage, or diabetes with three or more
major risk factors, or with a diabetes duration of >20 years
are at very high CV risk. Patients with diabetes duration
10 years without target organ damage plus any other
additional risk factor are at high CV risk. Young patients
(type 1 diabetes aged <35 years or type 2 diabetes aged
<50 years) with diabetes duration <10 years, without
other risk factors, are at moderate risk [16].1 We suggest that, in patients with diabetes,
aspirin (65e100 mg/d) use for the primary
prevention of CVD be based on CV risk fac-
tors, balancing the risk for ischemic events to
that of bleeding. (Not Graded)Lifestyle interventions
Weight gain is common in the first months after KT.
Although steroid therapy is known to contribute to
post-transplant weight gain [88,89], lifestyle factors
such as diet and physical activity play an important role
[90]. In addition, the association between physicalPlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orinactivity and poor outcomes in KTRs is well estab-
lished [91]. Low levels of physical activity are associated
with increased CV and all-cause mortality, as well as
with the metabolic syndrome and increased insulin and
triglyceride levels [92]. Furthermore, low physical ac-
tivity is also associated with abnormalities of glucose
metabolism in KTRs [93].
International guidelines on the management of type 2
diabetes acknowledge that increasing physical activity
improves glycaemic control, and should be encouraged in
all people with type 2 diabetes [71]. More specifically, the
European Society of Cardiology (ESC) e European Asso-
ciation for the Study of Diabetes (EASD) 2019 joint
guidelines on diabetes, pre-diabetes, and cardiovascular
diseases recommend moderate-to-vigorous physical ac-
tivity, notably a combination of aerobic and resistance
exercise, for 150 min/week for the prevention and
control of diabetes, unless contraindicated, such as when
there are severe comorbidities or a limited life expec-
tancy [16].
Unfortunately, there is a paucity of high-quality
research on the effects of physical activity on car-
diometabolic outcomes in KTRs, with most evidence being
anecdotal or from small observational studies. A system-
atic review and meta-analysis of randomized controlled
trials of exercise training in solid organ transplant re-
cipients showed no significant improvements in exercise
capacity or CV risk factors such as incidence of new-onset
diabetes after transplantation, but all effect estimates were
very imprecise [94]. More recently, both aerobic and
resistance training were shown to be well tolerated, and to
improve arterial stiffness and cardiorespiratory fitness in
KTRs [95,96], suggesting that the exercise-associated
benefits observed in the general population could also
apply to KTRs. The preliminary results of a multicentre,
controlled, prospective, nonrandomized study that
enrolled solid organ transplant recipients (21 KTRs) indi-
cate that supervised personalized physical activity for one
year is associated with significant reductions in body mass
index [97].
One non-randomized prospective trial addressed the
effect of lifestyle modification (comprising an exercise
program and weight loss counselling) in renal transplant
recipients with either PTDM or impaired glucose tolerance,
demonstrating a significant improvement 2-h postprandial
glucose levels after a mean follow-up of 8.2 months [98].
Conversely, only a significant reduction in percent fat mass
with no improvement in cardiometabolic risk factors (e.g.
blood pressure, fasting and 2-h plasma glucose, HbA1c)
was observed in KTRs with different glycaemic status
(normal, impaired fasting glucose, impaired glucose
tolerance, diabetes) subjected to 16 weeks of resistance
training (45e60 min 3 times per week) versus standard
care (no structured exercise) [99]. Finally, in a study that
assessed the effect of a 90-day pedometer-based physical
activity intervention on several metabolic parameters,
KTRs in the physical activity cohort were less likely to have
impaired fasting glucose at the end of the intervention
versus those in the usual care cohort (20.7% vs. 30.9%,lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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8 C. Conte et al.p Z 0.04). However, no significant difference was found
either at 4 or 12 months in weight gain, incidence of
PTDM, lipids, or eGFR [100].
While the 2009 KDIGO guidelines did not provide
specific dietary recommendations for the management of
PTDM [10], the nutritional management of diabetes mel-
litus in adult KTRs was addressed by the 2010 Caring for
Australasians with Renal Impairment (CARI) guidelines
[15]. However, the CARI guidelines acknowledged there
were no published studies up to September 2006 exam-
ining the safety and efficacy of dietary interventions for
the prevention and management of diabetes in adult KTRs.
We could not find any studies published since September
2006 specifically addressing nutrition therapy in KTRs
with PTDM. In a longitudinal cohort study that assessed
the prospective associations of fruit and vegetable intake
with risk of PTDM in stable KTRs, vegetable (but not fruit)
intake was associated with lower risk of PTDM, suggesting
that higher vegetable intake might be beneficial for PTDM
prevention [101]. A multicentre randomised controlled
trial to compare the outcomes of usual care to the effects
of exercise alone, and exercise combined with dietary
counselling, on physical functioning, quality of life and
post-transplantation weight gain in KTRs is currently
ongoing [102].
While awaiting for more specific evidence on dietary
interventions in the KT setting, it is reasonable to follow
the nutritional recommendations developed for the gen-
eral population with diabetes [16,17]. Weight loss in-
terventions in overweight and obese KTRs are addressed in
OBESITY of this document.1 We suggest encouraging lifestyle modifica-
tions including dietary changes, physical
exercise and, in overweight/obese patients,
weight loss. (Not Graded )
1 In adult KTRs, we recommend evaluation
with a lipid profile (total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides)
(1ØØOO)
2 We suggest repeat evaluation of lipid profile
8 (4) weeks after starting or adjusting
treatment, until the target is achieved, and
annually thereafter, unless otherwise clini-
cally indicated (Not Graded )Dyslipidaemias
Screening for dyslipidaemias
Cardiovascular disease is one of the leading causes of
death among KTRs [103,104]. Despite reductions in CV
disease and mortality after KT as compared with patients
who remain on dialysis, CV risk is higher than in the
general population [105e107]. Both traditional and non-
traditional CV risk factors contribute to the increased
risk observed in this population, with some risk factors
being exacerbated by certain immunosuppressive drugs.
Cyclosporine, corticosteroids, sirolimus, and everolimusPlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.ornegatively impact on lipid profile, generally to a greater
extent than tacrolimus, whereas no significant effect is
reported with mycophenolate or azathioprine [108]. Due
to a paucity of data on CV risk assessment and in-
terventions aimed at reducing CV risk in KTRs, strategies
to reduce CV risk are largely extrapolated from other
patient populations. Individuals with chronic kidney dis-
ease (CKD) are considered at high (stage 3 CKD) or very-
high risk (stage 4e5 CKD or on dialysis). In KTRs, the risk
of atherosclerotic CV disease is determined, at least in
part, by the increased risk associated with CKD itself. As
such, aggressive management of CV risk factors, including
atherosclerotic dyslipidaemia, is mandatory. Despite the
lack of studies specifically addressing the need for dysli-
pidaemia assessment in adult KTRs, we agree with the
KDIGO Clinical Practice Guideline for Lipid Management
in CKD in recognizing that initial evaluation of the lipid
profile is non-invasive, inexpensive, and likely beneficial,
as it allows determining the type and severity of dysli-
pidaemia [21,109].
In the absence of evidence specifically relating to lipid
monitoring in KTRs, it is reasonable to adopt the same
recommendations issued by recent international guide-
lines on lipid management in the general population
[18,20]. Repeat evaluation is suggested 4e12 weeks after
starting or adjusting treatment, in order to assess patient
adherence and treatment efficacy. Once the treatment
target is achieved, periodic annual remeasurements are
suggested, unless more frequent evaluation is clinically
indicated (e.g. change in immunosuppressive regimen or
initiation of medications known to interfere with current
lipid-lowering treatment).Ldl targets
In the Assessment of LEscol in Renal Transplantation
Study (ALERT) trial, a 32% reduction from baseline in LDL
cholesterol levels by fluvastatin, with a mean difference
of 39 mg/dL (1.0 mmol/L) between the treatment and the
placebo arms throughout the study, led to a significantlterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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1 We suggest a 50% LDL-C reduction from
baseline and an LDL-C goal of <2.6 mmol/L
(<100 mg/dL) for most KTRs (Not Graded ).
2 We suggest a 50% LDL-C reduction from
baseline and an LDL-C goal of <1.8 mmol/L
(<70 mg/dL) in KTRs at very high CV risk (e.g.
with previous CV events) (Not Graded )
Metabolic alterations in kidney transplant 9reduction in the risk of cardiac death or nonfatal
myocardial infarction (MI), and a non-significant reduc-
tion in coronary death or non-fatal MI compared with
placebo [110]. Subgroup analysis of patients with sys-
temic lupus erythematosus showed a LDL-reduction of
nearly 30% and a borderline significant 73.4% reduction in
the risk of major cardiac events (P Z 0.064) [111]. A
systematic review and metanalysis of randomized trials
that assessed the benefits and harms of statin therapy for
CKD patients, the mean absolute reduction from baseline
in LDL cholesterol was 43.5 mg/dL (1.1 mmol/L) in KTRs,
the magnitude of reduction being similar across different
stages of CKD (not on dialysis, dialysis, KT) [112]. While
statin therapy reduced major CV events in CKD patients
not on dialysis, the effects in KTRs were uncertain (RR
0.84 [CI 0.66e1.06]), in lower-quality evidence. Similar
effects were found for MI and stroke (RR 0.70 [CI
0.48e1.01] and RR 1.18 [0.62e2.24], respectively, in
KTRs). A more recent Cochrane review that specifically
addressed statin use in KTRs yielded similar results [113].
Of note, the statin dose was relatively low in the studies
included in these metanalyses and, due to insufficient
information, it was unclear whether treatment benefits
from statins were dependent on reductions in serum
cholesterol.
Finally, in a 12-month randomized open-label, pro-
spective study, statin treatment (rosuvastatin or atorvas-
tatin 10 mg) did not delay the progression of coronary
artery calcification (CAC) in KTRs [114].
In light of the available data, it appears that reductions
in LDL cholesterol of at least 30% are needed to achieve
some CV benefit in KTRs. In the absence of trials
addressing the relationship between LDL reduction and CV
events in this population, it is reasonable to follow rec-
ommendations issued for patients at high or very high risk
in the general population.
Current international guidelines agree on achieving
50% reductions in LDL cholesterol in high- and very-
high risk patients (those with documented atheroscle-
rotic CV disease, type 1 or type 2 diabetes, very high
levels of individual risk factors, or CKD) [18,20]. How-
ever, the European guidelines set more stringent
treatment targets (LDL cholesterol <70 mg/dL
[<1.8 mmol/L] and <55 mg/dL [<1.4 mmol/L] for high-
and very-high risk patients, respectively) as compared
with American guidelines (LDL cholesterol <100 mg/dL
[<2.6 mmol/L] and <70 mg/dL [<1.8 mmol/L] for high-
and very-high risk patients, respectively). Given the
potential risk of increasing the dose of lipid lowering
medications due to potential drugedrug interactions
[115], and the lack of evidence specifically relating to
the KTR population, a reduction 50% from baseline
LDL cholesterol levels aiming at LDL cholesterol at least
<100 mg/dL (<2.6 mmol/L) and <70 mg/dL
(<1.8 mmol/L) for high- and very-high risk
patients, respectively, appears to be of potential benefit
and more realistic.Please cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orManagement of dyslipidaemias
We could not find studies specifically addressing the role
of lifestyle interventions in the management of dyslipi-
daemia in KTRs. In the absence of high quality studies on
the effect of lifestyle interventions in KTRs with dyslipi-
daemia, and taking into account the evidence for the
benefit of providing lifestyle interventions for the treat-
ment of dyslipidaemia in the general population, it is
reasonable to follow the lifestyle recommendations issued
for the general population [18,20].
Statins (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors) are the pillar of lipid-lowering man-
agement, providing significant reductions in CV morbidity
and mortality in the general population [116]. Trials that
assessed the role of statin therapy (either atorvastatin or
rosuvastatin) in patients on haemodialysis, with or
without diabetes, failed to demonstrate a reduction in the
risk of CV disease [117,118]. However, in the Study of Heart
and Renal Protection (SHARP) treatment with simvastatin
plus ezetimibe was effective in reducing CV events in-
dividuals with CKD [119]. In general, it appears that the CV
benefit of reducing LDL cholesterol with statin therapy
decreases with worsening renal function [120], high-
lighting the importance of treating CKD patients when GFR
is moderately reduced and the likelihood of achieving
clinically relevant reductions in LDL cholesterol is higher,
and that more aggressive treatment is needed to achieve
similar benefits as in individuals without CKD.
The ALERT trial demonstrated a significant reduction in
the risk of cardiac death or nonfatal myocardial infarction
(MI), although it failed to demonstrate a significant effect
on coronary death or non-fatal MI compared with placebo
[110]. Of note, in a subgroup analysis of the ALERT trial,
statin treatment was associated with a more pronounced
reduction in major CV events, as well as with a significant
reduction in cardiac death in KTRs with the metabolic
syndrome as compared with those without [121].
A Cochrane systematic review of the benefits and harms
of statins in KTRs (nZ 3465) free of coronary heart diseaselterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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1 We suggest that all patient should receive
healthy lifestyle advice (Not Graded )
2 In adult kidney transplant recipients, we
suggest treatment with a statin as first line
(2ØØØO).
3 We suggest ezetimibe or PCSK9 inhibitors as
alternative or additional therapy to limit
statin dose in ktrs with high LDL-C levels (Not
Graded )
10 C. Conte et al.concluded that statins (generally at a simvastatin dose
equivalent to 10 mg/d) may reduce CV mortality (RR 0.68,
95% CI 0.45 to 1.01) and, based on the ALERT trial, major CV
events (RR 0.84, 95% CI 0.66 to 1.06) and fatal or non-fatal
MI (RR 0.70, 95% CI 0.48 to 1.01) [113]. However, the
magnitude of these effects remains uncertain, as confi-
dence intervals were wide and included the possibility of
no effect. Statin treatment had uncertain effects on all-
cause mortality (RR 1.08, 95% CI 0.63 to 1.83). Similar
findings had been reported by the same authors in a
previous systematic review and metanalysis [112]. More
recently, another metanalysis of randomized trials of statin
versus placebo across CKD stages including KT confirmed
that statins may reduce CV mortality in KTRs, but too few
KTRs have been included in lipid lowering trials to draw
firm conclusions [122].
A retrospective longitudinal cohort study demonstrated
that KTRs on statin therapy 50% of the post-transplant
follow-up time (high statin users) had a significant 52%
lower risk of developing graft loss compared to those on
statin therapy <50% of the post-transplant follow-up time
(low statin users), independent of race (African American
versus not African American) [123]. High statin use did not
influence the incidence of acute rejection, and significantly
reduced the risk of death only in African American KTRs.
The results of a recent survival meta-analysis suggest
that statin use is associated with improved patient and
graft survival after KT [124].
Despite some degree of uncertainty, only statins
demonstrated to reduce CV events in at least one large and
well-conducted RCT, and therefore we suggest using sta-
tins as first-line treatment for lipid lowering. The statin
dose should be adjusted according to renal function, as
indicated by the KDIGO Clinical Practice Guideline for Lipid
Management in CKD [109]. Potential adverse effects such
as dysglycaemia [39] should be taken into account, and
drugedrug interactions should be considered when
selecting and dosing a lipid-lowering agent in patients on
immunosuppressive regimens [115].
Evidence supporting the use of ezetimibe, either alone
or on top of statin therapy, comes from small, non-
controlled studies. Combination of simvastatin 10 mg
with ezetimibe 10 mg for 6 months was well tolerated, and
resulted in reductions in LDL cholesterol of nearly 50%,
with more than half of patients reaching the target LDL
level of <100 mg/dL in a relatively small, non-randomized
trial in Korean KTRs [125]. The results of another small
study in which KTRs who were treated with ezetimibe
alone or in conjunction with a statin for a mean of 18  6
months suggest that ezetimibe might be well tolerated and
effective in reducing LDL cholesterol in KTRs with hyper-
cholesterolemia [126]. To the best of our knowledge, no
outcome data are available for this drug in KTRs.
We could not find any study on proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors in KTRs. These
monoclonal antibodies provide significant reductions in
LDL cholesterol levels and CV events [127], are unlikely to
interact with other drugs [128] and might be a promising
therapeutic option in patients with reduced renal function,Please cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.oralthough data are lacking in patients with more severe
impairments [129].Obesity
Weight gain after transplantation is very common,
occurring in up to 50% of KTRs [130,131], mainly in the
first year after KT [132] and due to abdominal accumu-
lation of body fat mass [89,133,134]. Factors contributing
to weight gain after KT include corticosteroid therapy,
improved appetite due to correction of uraemia and
elimination of dietary restrictions [132]. Obesity is
strongly associated with reduced long-term patient- and
graft survival [135e137], with the risks for adverse
outcome progressively increasing with increasing body
mass index (BMI) [138]. Therefore, weight reduction in
obese KTRs may provide beneficial effects on graft and
patient survival.
Given the impact of obesity on patient and graft
survival in KTRs [139], we suggest screening KTRs for
obesity at each visit, by measuring height and weight to
calculate BMI. In the general population abdominal
obesity, as evidenced by increased waist circumference,
has been associated with increased CVD risk more
strongly than BMI [140,141]. There is evidence that
waist circumference is associated with increased mor-
tality after adjustment for BMI in KTRs, whereas higher
BMI was associated with lower mortality after adjust-
ment for waist circumference [142]. These data suggest
that waist circumference may better predict long-term
survival in KTRs, and we suggest measuring waist
circumference in when weight and physical appearance
suggest obesity, but BMI is < 30 kg/m2.
Only one small randomized trial evaluated the effect of
dietary advice versus standard care in KTRs (normal
weight, overweight and obese) [143]. However, in this
study no significant changes in weight or weight circum-
ference were observed during follow-up. Total cholesterol,
LDL cholesterol and triglycerides declined only in thelterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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1 We suggest assessing obesity at each visit
(Not Graded). Measure height and weight at
each visit to calculate BMI (2ØØØO). Mea-
sure waist circumference when weight and
physical appearance suggest obesity, but
BMI is < 30 kg/m2 (2ØØOO).
2 We suggest offering a weight-reduction
program including dietary and physical ac-
tivity recommendations to all obese KTRs
(Not Graded). Bariatric surgery could be
considered as an option in adult KTRs who
have failed to lose weight or to maintain
long-term weight loss despite appropriate
non-surgical interventions (2ØØOO).
BMI, body mass index; KTRs, kidney transplant
recipients.
Metabolic alterations in kidney transplant 11intervention group. In a very small study that assessed the
effect of an intensive lifestyle intervention comprising
physical exercise, behavioural interventions and nutri-
tional guidance in obese KTRs, after 12 months the inter-
vention group was weight-stable and had improvements
in body composition (greater lean mass), whereas the BMI
of patients in the control group increased on average from
38 to 46 kg/m2 [144].
Trials assessing the effect of lifestyle interventions on
the prevention of weight gain after KT are currently
ongoing [102,145].
In the absence of high quality studies on the effect of
lifestyle interventions in obese KTRs, and taking into ac-
count the evidence for the benefit of providing lifestyle
interventions for the treatment of obesity in the general
population, it is reasonable to follow the lifestyle recom-
mendations issued for the general population [19,22].
Bariatric surgery has been shown to be superior to
nonsurgical obesity management in reducing all-cause
mortality in the general population with obesity [146].
Indications to bariatric surgery include class III obesity
(BMI  40 kg/m2) or class II obesity (BMI 35e40 kg/m2)
with comorbidities in which surgically induced weight loss
is expected to improve the disorder [147]. In recent years,
given the metabolic benefits associated with bariatric
surgery in patients with diabetes, it has been recognized
that metabolic surgery should also be considered as an
option to treat type 2 diabetes in patients with class I
obesity (BMI 30.0e34.9 kg/m2) and inadequately
controlled hyperglycaemia despite optimal medical treat-
ment [148].
Several small case series have reported the outcomes of
bariatric surgery (either Roux-en-Y gastric bypass [RYGB]
or laparoscopic vertical sleeve gastrectomy [LVSG]) in KTRs
[149]. Excess weight loss ranged from 31 to 61% in these
series, and mortality rates were equal to those among
patients on the waiting list. Overall, RYGB and LVSG
showed comparable results with low mortality and
complication rates. However, in the long term, RYGB may
increase the risk of hyperoxaluria and nephrocalcinosis
[150], and possibly the risk of acute rejection by reducing
drug exposure [151] in KTRs. A comparison between
morbidly obese KTRs treated with bariatric surgery or
standard lifestyle recommendations after KT found that
patients treated with bariatric surgery had significantly
lower BMI at 6 months after KT, and significantly more
patients had slow and delayed graft function in the life-
style group [152]. No differences in metabolic and safety
outcomes were detected. More recently, a retrospective
study compared KTRs who underwent bariatric surgery
with controls matched for age, sex, and time elapsed since
transplantation [153]. Mean follow-up was 2.4 years. Im-
provements in renal function, graft survival, and obesity-
related co-morbidities were found in KTRs who under-
went bariatric surgery versus controls. No major effects of
bariatric surgery on the absorption of immunosuppressive
drugs have been described. Based on the available evi-
dence, bariatric surgery in KTRs appears to be effective for
weight loss and associated with low rates of complicationsPlease cite this article as: Conte C et al., Management of metabolic a
statement of the Italian Society of Nephrology (SIN), the Italian Society
(SID), Nutrition, Metabolism & Cardiovascular Diseases, https://doi.orand mortality. No long-term studies are available that
assessed the effect of bariatric surgery o CV outcomes. We
suggest that bariatric surgery could be considered as an
option in adult KTRs who have failed to lose weight or to
maintain long-term weight loss despite appropriate non-
surgical interventions.Conclusions
Post-transplantation diabetes mellitus, dyslipidaemias and
overweight/obesity are common metabolic disturbances
among KTRs that may undermine graft and/or recipient
outcomes [7e9]. Increasing awareness among healthcare
professionals involved in the management of KTRs is of
paramount importance to systematically implement
timely and accurate screening for metabolic alterations in
KTRs. Early detection allows early implementation of
appropriate management strategies, although more
research is needed to develop robust recommendations on
several aspects in the setting of KT, including glycaemic
and LDL cholesterol targets in PTDM, choice of glucose and
lipid lowering agents, management of overweight/obesity.
These aspects should be the focus of future research to fill
the gaps in current knowledge. This joint position state-
ment is based on currently available evidence on the
prevention, diagnosis and treatment of metabolic alter-
ations in KTRs and will support healthcare professionals in
the decision-making process in this context. The choice of
treatment should be individualised and based on several
factors, such as the expected risk/benefit ratio for the in-
dividual patient, her/his preferences, and the availability of
healthcare resources.lterations in adult kidney transplant recipients: A joint position
for Organ Transplantation (SITO) and the Italian Diabetes Society
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